The effectiveness of Vagus nerve stimulation in the treatment of Alzheimer’s disease and Parkinson’s disease: a systematic review
The effectiveness of Vagus nerve stimulation in the treatment of Alzheimer’s disease and Parkinson’s disease: a systematic review
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are progressive neurodegenerative disorders with limited disease-modifying treatments. The locus coeruleus (LC), a brainstem nucleus and key source of noradrenaline, is one of the earliest sites of degeneration in both conditions. LC dysfunction contributes to neuroinflammation and cognitive decline. Vagus nerve stimulation (VNS) offers a novel therapeutic approach for these diseases by indirectly activating the LC, enhancing noradrenergic signalling, and reducing neuroinflammatory processes. Two main types of VNS exist:
• Invasive VNS, involving surgical implantation
• Transcutaneous VNS (tVNS), a non-invasive alternative targeting auricular or cervical branches.
VNS may therefore hold promise as a disease-modifying strategy in AD and PD. So we aim to systematically evaluate the effectiveness of VNS in treating AD and PD. The review focuses on both human and animal studies, with particular attention to cognitive, motor, and inflammatory outcomes.
Rhys-Binney, Cadi
07617c2f-cc89-4bd8-bde6-1b4027f7b69e
Hou, Ruihua
470bdcbc-93a9-4dad-aac5-26d455c34376
18 June 2025
Rhys-Binney, Cadi
07617c2f-cc89-4bd8-bde6-1b4027f7b69e
Hou, Ruihua
470bdcbc-93a9-4dad-aac5-26d455c34376
Rhys-Binney, Cadi and Hou, Ruihua
(2025)
The effectiveness of Vagus nerve stimulation in the treatment of Alzheimer’s disease and Parkinson’s disease: a systematic review.
36th World Congress of Neuropsychopharmacology(CINP) Congress, , Melbourne, Australia.
15 - 18 Jun 2025.
Record type:
Conference or Workshop Item
(Poster)
Abstract
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are progressive neurodegenerative disorders with limited disease-modifying treatments. The locus coeruleus (LC), a brainstem nucleus and key source of noradrenaline, is one of the earliest sites of degeneration in both conditions. LC dysfunction contributes to neuroinflammation and cognitive decline. Vagus nerve stimulation (VNS) offers a novel therapeutic approach for these diseases by indirectly activating the LC, enhancing noradrenergic signalling, and reducing neuroinflammatory processes. Two main types of VNS exist:
• Invasive VNS, involving surgical implantation
• Transcutaneous VNS (tVNS), a non-invasive alternative targeting auricular or cervical branches.
VNS may therefore hold promise as a disease-modifying strategy in AD and PD. So we aim to systematically evaluate the effectiveness of VNS in treating AD and PD. The review focuses on both human and animal studies, with particular attention to cognitive, motor, and inflammatory outcomes.
Text
CINP Poster
- Version of Record
Restricted to Registered users only
Request a copy
More information
Published date: 18 June 2025
Venue - Dates:
36th World Congress of Neuropsychopharmacology(CINP) Congress, , Melbourne, Australia, 2025-06-15 - 2025-06-18
Identifiers
Local EPrints ID: 507503
URI: http://eprints.soton.ac.uk/id/eprint/507503
PURE UUID: 2007a984-58d4-4c99-8e48-ccac86399e30
Catalogue record
Date deposited: 10 Dec 2025 17:52
Last modified: 11 Dec 2025 02:41
Export record
Contributors
Author:
Cadi Rhys-Binney
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
